US 11,891,603 B2Granted

Antisense oligonucleotides that bind to exon 51 of human dystrophin pre-mRNA

AssigneeThe Governors of the University of Alberta

InventorsToshifumi Yokota, Yusuke Echigoya

Life of this patent

Estimating the term…

Abstract

The present invention relates to a therapeutic antisense oligonucleotide which binds to exon 51 of the human dystrophin pre-mRNA to induce exon skipping, and conjugates and compositions thereof for the treatment of DMD.

Claims10

Dependent claims

A modified synthetic antisense oligonucleotide analogue consisting of SEQ ID NO:1 (Ac0), SEQ ID NO:2 (Ac5), SEQ ID NO:3 (Ac26), SEQ ID NO:4 (Ac30), or SEQ ID NO:5 (Ac48).

Dependencies are inferred from the claim text.

Facts

Application: 17/466,833Filed 3 Sep 2021 · continuation
Priority: GB 171180921 Jul 2017
Published: US 2021/0395741 A123 Dec 2021
Granted: 6 Feb 2024
Term ends: Not estimatedThe source records don’t support an estimate.

Classification12 codes

A61K 31/7105
Compounds having three or more nucleosides or nucleotides: natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine,…
C12N 15/113
DNA or RNA fragments; Modified forms thereof ; Non-coding nucleic acids having a biological activity: non-coding nucleic acids modulating the…
A61K 47/645
Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is…:…
A61P 21/00
Drugs for disorders of the muscular or neuromuscular system

Family

PCT/CA2018/050881Parent of this continuation · filed 20 Jul 2018
US 2021/0395741 A1Pre-grant publication · published 23 Dec 2021
Application16/632,827Parent of this continuation
US 11,142,767 B2Parent of this continuation
US 2020/0362336 A1Published application
US 11,891,603 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results